The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Grishina D.A.

Sechenov First Moscow State Medical University (Sechenov University)

Grinyuk V.V.

Sechenov First Moscow State Medical University (Sechenov University)

Nodel M.R.

Sechenov First Moscow State Medical University (Sechenov University)

Tyurina A.Yu.

Sechenov First Moscow State Medical University (Sechenov University)

Mkhitaryan E.A.

Russian Gerontological Research and Clinical Center of the Pirogov Russian National Research Medical University

Chervyakova Ya.I.

Sechenov First Moscow State Medical University (Sechenov University)

Diagnosis of Alzheimer’s disease using biological markers in corticobasal syndrome

Authors:

Grishina D.A., Grinyuk V.V., Nodel M.R., Tyurina A.Yu., Mkhitaryan E.A., Chervyakova Ya.I.

More about the authors

Read: 375 times


To cite this article:

Grishina DA, Grinyuk VV, Nodel MR, Tyurina AYu, Mkhitaryan EA, Chervyakova YaI. Diagnosis of Alzheimer’s disease using biological markers in corticobasal syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(8):133‑139. (In Russ.)
https://doi.org/10.17116/jnevro2025125081133

Recommended articles:
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
Como­rbidity of depression and deme­ntia: epidemiological, biological and therapeutic aspe­cts. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):113-121
Cognitive impairment in bili­nguals with neurological diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):26-29
Modern aspe­cts of chro­nic cere­bral ischemia pathogenetic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):106-113
Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):8-16
Differentiated approach to cognitive reha­bilitation of patients after stroke. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6):5-11

References:

  1. Yakhno NN, Zakharov VV, Lokshina AB, et al. Demencii. 3-e izd. M.: MEDpress-inform. 2011;374. (In Russ.).
  2. Shpilyukova YuA, Fedotova EYu, Illarioshkin SN. Corticobasal syndrome as a phenotype of various neurodegenerative disorders: a case series. Annaly klinicheskoi I eksperimental’noi nevrologii. 2022;16(1):64-70. (In Russ.). https://doi.org/10.54101/ACEN.2022.1.9
  3. Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology.2013;80(5):496-503.  https://doi.org/10.1212/WNL.0b013e31827f0fd1
  4. Lee SE, Rabinovici GD, Mayo MC, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol. 2011;70(2):327-340.  https://doi.org/10.1002/ana.22424
  5. Whitwell JL, Jack CR Jr, Boeve BF, et al. Imaging correlates of pathology in corticobasal syndrome. Neurology. 2010;75(21):1879-1887. https://doi.org/10.1212/WNL.0b013e3181feb2e8
  6. Koga S, Josephs KA, Aiba I, et al. Neuropathology and emerging biomarkers in corticobasal syndrome. J Neurol Neurosurg Psychiatry. 2022;93(9):919-929.  https://doi.org/10.1136/jnnp-2021-328586
  7. Mesulam MM, Rogalski EJ, Wieneke C, et al. Primary progressive aphasia and the evolving neurology of the language network. Nat Rev Neurol. 2014;10:554-569.  https://doi.org/10.1038/nrneurol.2014.159
  8. Di Stefano F, Kas A, Habert MO, et al. The phenotypical core of Alzheimer’s disease-related and nonrelated variants of the corticobasal syndrome: A systematic clinical, neuropsychological, imaging, and biomarker study. Alzheimers Dement. 2016;12(7):786-795.  https://doi.org/10.1016/j.jalz.2016.02.005
  9. Hassan A, Whitwell JL, Josephs KA. The corticobasal syndrome-Alzheimer’s disease conundrum. Expert Rev Neurother. 2011;11(11):1569-1578. https://doi.org/10.1586/ern.11.153
  10. Shir D, Pham NTT, Botha H, et al. Clinicoradiologic and Neuropathologic Evaluation of Corticobasal Syndrome. Neurology. 2023;101(3):e289-e299. https://doi.org/10.1212/WNL.0000000000207397
  11. Constantinides VC, Paraskevas GP, Efthymiopoulou E, et al. Clinical, neuropsychological and imaging characteristics of Alzheimer’s disease patients presenting as corticobasal syndrome. J Neurol Sci. 2019;398:142-147.  https://doi.org/10.1016/j.jns.2019.01.046
  12. Remoli G, Schilke ED, Magi A, et al. Neuropathological hints from CSF and serum biomarkers in corticobasal syndrome (CBS):a systematic review. Neurol Res Pract. 2024;6(1):1.  https://doi.org/10.1186/s42466-023-00294-0
  13. Boyd C, Tierney M, Wassermann E, et al. Sensitivity and specificity of new criteria for the diagnosis of corticobasal degeneration. Neurology. 2015;84(14 Supplement):P5.010.  https://www.neurology.org/doi/10.1212/WNL.84.14_supplement.P5.010
  14. Constantinides VC, Paraskevas GP, Boufidou F, et al. Cerebrospinal fluid biomarker profiling in corticobasal degeneration: application of the AT(N) and other classification systems. Parkinsonism Relat Disord. 2021;82:44-49.  https://doi.org/10.1016/j.parkreldis.2020.11.016
  15. Sakae N, Josephs KA, Litvan I, et al. Clinicopathologic subtype of Alzheimer’s disease presenting as corticobasal syndrome. Alzheimers Dement. 2019;15:1218-1228. https://doi.org/10.1016/j.jalz.2019.04.011
  16. Hu WT, Rippon GW, Boeve BF, et al. Alzheimer’s disease and corticobasal degeneration presenting as corticobasal syndrome. Mov Disord. 2009;24:1375-1379. https://doi.org/10.1002/mds.22574
  17. Shelley BP, Hodges JR, Kipps CM, et al. Is the pathology of corticobasal syndrome predictable in life? Mov Disord 2009;24:1593-1599. https://doi.org/10.1002/mds.22558
  18. McMillan CT, Boyd C, Gross RG, et al. Multimodal imaging evidence of pathology-mediated disease distribution in corticobasal syndrome. Neurology. 2016;87:1227-1234. https://doi.org/10.1212/WNL.0000000000003119
  19. Grishina DA, Khayalieva NA, Grinyuk VV, et al. Diagnosis of Alzheimer’s disease by using biological markers in posterior cortical atrophy. Nevrologiya, neiropsikhiatriya, psikhosomatika. 2024;16(2):47-53. (In Russ.). https://doi.org/10.14412/2074-2711-2024-2-47-53
  20. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. https://doi.org/10.1212/WNL.0b013e31821103e6
  21. Medvedeva AV, Grishina DA. The possibilities of differential diagnosis of primary progressive aphasia. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(9):121-127. (In Russ.). https://doi.org/10.17116/jnevro2022122091121
  22. Arienti F, Lazzeri G, Vizziello M, et al. Unravelling genetic factors underlying corticobasal syndrome: A systematic review. Cells. 2021;10(1):1-15.  https://doi.org/10.3390/CELLS10010171
  23. Navarro E, De Andrés C, Guerrero C, et al. Corticobasal Syndrome in a Family with Early-Onset Alzheimer’s Disease Linked to a Presenilin-1 Gene Mutation. Mov Disord Clin Pract. 2015;2(4):388-394.  https://doi.org/10.1002/mdc3.12212
  24. Constantinides VC, Tentolouris-Piperas V, Paraskevas GP, et al. Hippocampal subfield volumetry in corticobasal syndrome of diverse underlying pathologies. J Neurol. 2023;270(4):2059-2068. https://doi.org/10.1007/s00415-022-11538-5
  25. Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. Lancet Neurol. 2021;20:484-496.  https://doi.org/10.1016/S1474-4422(21)00066-1
  26. Parfenov VA, Grishina DA, Tyurina AYu. Alzheimer’s disease: diagnosis and treatment, errors in patient management. Nevrologiya, neiropsikhiatriya, psikhosomatika. 2024;16(2):95-100. (In Russ.). https://doi.org/10.14412/2074-2711-2024-2-95-100
  27. Grishina DA, Lokshina AB, Sokolov EA. Management of patients with cognitive impairment in old age. Nevrologiya, neiropsikhiatriya, psikhosomatika. 2024;16(6):118-124. (In Russ.). https://doi.org/10.14412/2074-2711-2024-6-118-124
  28. Schoonenboom NS, Reesink FE, Verwey NA, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology. 2012;78(1):47-54.  https://doi.org/10.1212/WNL.0b013e31823ed0f0
  29. Balasa M, Gelpi E, Antonell A, et al. Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology. 2011;76:1720-1725. https://doi.org/10.1212/WNL.0b013e31821a44dd
  30. Wu W, Ji Y, Wang Z, et al. The FDA-approved anti-amyloid-beta monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials. Eur J Med Res. 2023;28(1):544.  https://doi.org/10.1186/s40001-023-01512-w

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.